RxDoctor Payments Data

John McCoy

Psychiatric/Mental Health · Waco, TXNPI 1184189110

Payments from drug & device makers

$3,937in general payments, 2019–2025

Across 254 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$812
  • AbbVie$782
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$702
  • Sunovion Pharmaceuticals Inc.$554
  • Otsuka America Pharmaceutical, Inc.$452
  • Neurocrine Biosciences, Inc.$416
  • plus $219 from 3 others

What the payments were for

  • Food & beverage$3,67493%
  • Education$2637%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,937 in reported general payments places this provider in the 85th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$7,261
Medicare patients
30
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate35$310,703
AustedoDeutetrabenazine44$303,202
Abilify MaintenaAripiprazole53$146,338
RexultiBrexpiprazole38$61,598
Invega SustennaPaliperidone Palmitate15$42,385
VraylarCariprazine Hcl26$37,951
CaplytaLumateperone Tosylate11$17,603
Lurasidone Hcl31$12,688
Ziprasidone Hcl43$6,548
Perphenazine20$2,886
Aripiprazole58$2,246
Buspirone Hcl117$2,136
Hydroxyzine Pamoate86$1,622
Oxcarbazepine32$1,591
Fluphenazine Decanoate23$1,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$416$310,70335 claims
Teva Pharmaceuticals USA, Inc.Austedo, Loxapine$812$303,41163 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$452$207,93591 claims
Johnson & JohnsonInvega Sustenna$38$42,38515 claims
AbbVieVraylar$782$37,95126 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$702$17,60311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →